Detail akcie Penumbra online

Business Summary: Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Penumbra Inc revenues increased 16% to $324.1M. Net income increased from $11M to $39.2M. Revenues reflect Vascular segment increase of 21% to $226.5M, Neuro segment increase of 7% to $97.6M, United States segment increase of 23% to $256.9M. Net income benefited from Research and Development - Other decrease of 11% to $19.9M (expense), Amort Intangibles excl Goodwill in SGA decrease of 96% to $104K (expense).